Key result
This review summarizes how common genetic variants, including CYP2C19 and VKORC1, influence the absorption, metabolism, and action of clopidogrel, warfarin, and dabigatran.
This review highlights the role of genetic polymorphisms in the variable response to common antiplatelet and anticoagulant therapies, emphasizing the potential for personalized medicine.
Should not yet alter prescribing of antiplatelet or anticoagulant drugs; leaves open the need for outcome trials to guide adoption.
Genetic polymorphisms are thought to contribute to the wide intraindividual variability in antiplatelet and anticoagulant drug response. Pharmacogenetics is the study of how genetic variants influence drug response and how the adoption of a more personalized approach in antiplatelet and anticoagulant therapy may help to minimize harmful drug effects and optimize care for individual patients. However, due to sometimes conflicting evidence, the uptake of pharmacogenetics in the clinical setting has been slow. In this article, we review the genetic mechanisms contributing to the variability in response to three commonly used and emerging antiplatelet and anticoagulant drug therapies, namely clopidogrel, warfarin and dabigatran. We will focus on common genetic variants that influence the absorption, metabolism and/or action of these agents, including CYP2C19 (*2, *3 and *17), CYP3A4, CYP3A5, CYP2C9, ABCB1, P2RY12, CYP2C9 (*2/*3), VKORC1 and CESI.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2013) conducted a review in Antiplatelet and anticoagulant drug response variability. Pharmacogenetics (clopidogrel, warfarin, dabigatran) was evaluated. This review summarizes how common genetic variants, including CYP2C19 and VKORC1, influence the absorption, metabolism, and action of clopidogrel, warfarin, and dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: